Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic

8Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

High levels of macrophage migration inhibitory factor (MIF) in patients with cancer are associated with poor prognosis. Its redox-dependent conformational isoform, termed oxidized MIF (oxMIF), is a promising tumor target due to its selective occurrence in tumor lesions and at inflammatory sites. A first-generation anti-oxMIF mAb, imalumab, was investigated in clinical trials in patients with advanced solid tumors, where it was well tolerated and showed signs of efficacy. However, imalumab has a short half-life in humans, increased aggregation propensity, and an unfavorable pharmacokinetic profile. Here, we aimed to optimize imalumab by improving its physicochemical characteristics and boosting its effector functions. Point mutations introduced into the variable regions reduced hydrophobicity and the antibodies’ aggregation potential, and increased plasma half-life and tumor accumulation in vivo, while retaining affinity and specificity to oxMIF. The introduction of mutations into the Fc region known to increase antibody-dependent cellular cytotoxicity resulted in enhanced effector functions of the novel antibodies in vitro, whereas reduced cytokine release from human peripheral blood mononuclear cells in the absence of target antigen by the engineered anti-oxMIF mAb ON203 versus imalumab reveals a favorable in vitro safety profile. In vivo, ON203 mAb demonstrated superior efficacy over imalumab in both prophylactic and established prostate cancer (PC3) mouse xenograft models. In summary, our data highlight the potential of the second-generation anti-oxMIF mAb ON203 as a promising immunotherapy for patients with solid tumors, warranting clinical evaluation.

References Powered by Scopus

QuPath: Open source software for digital pathology image analysis

4454Citations
N/AReaders
Get full text

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγrIIIa gene

1733Citations
N/AReaders
Get full text

Macrophage migration inhibitory factor: A regulator of innate immunity

1484Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis

6Citations
N/AReaders
Get full text

Host derived macrophage migration inhibitory factor expression attenuates anti-tumoral immune cell accumulation and promotes immunosuppression in the tumor microenvironment of head and neck squamous cell carcinoma

1Citations
N/AReaders
Get full text

Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of Cancer

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Rossmueller, G., Mirkina, I., Maurer, B., Hoeld, V., Mayer, J., Thiele, M., … Schinagl, A. (2023). Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic. Molecular Cancer Therapeutics, 22(5), 555–569. https://doi.org/10.1158/1535-7163.MCT-22-0676

Readers' Seniority

Tooltip

Professor / Associate Prof. 2

50%

PhD / Post grad / Masters / Doc 1

25%

Researcher 1

25%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 3

60%

Agricultural and Biological Sciences 1

20%

Engineering 1

20%

Save time finding and organizing research with Mendeley

Sign up for free